Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies

(2020) Andreas Viardot et al.   ANNALS OF HEMATOLOGY

Actin Cytoskeleton Straddling the Immunological Synapse between Cytotoxic Lymphocytes and Cancer Cells

(2019) Hannah Wurzer et al.   Cells

CD20-TCB (RG6026), A NOVEL “2:1” FORMAT T-CELL-ENGAGING BISPECIFIC ANTIBODY, INDUCES COMPLETE REMISSIONS IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA

(2019) M.J. Dickinson et al.   HEMATOLOGICAL ONCOLOGY

T Cell–Activating Bispecific Antibodies in Cancer Therapy

(2019) Asaad Trabolsi et al.   JOURNAL OF IMMUNOLOGY

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

(2019) Ann-Marie E Bröske et al.   BLOOD

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

(2019) Martin Hutchings et al.   BLOOD

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

(2019) Franck Morschhauser et al.   BLOOD

CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy

(2018) Ryuma Tokunaga et al.   CANCER TREATMENT REVIEWS

IFN-γ-induced chemokines are required for CXCR3-mediated T cell recruitment and anti-tumor efficacy of anti-HER2/CD3 bispecific antibody

(2018) Ji Li et al.   CLINICAL CANCER RESEARCH

CD20-TCB with obinutuzumab pretreatment as next generation treatment of hematological malignancies

(2018) Marina Bacac et al.   CLINICAL CANCER RESEARCH

CAR T cell immunotherapy for human cancer

(2018) Carl H. June et al.   SCIENCE

Overview of the Mechanisms that May Contribute to the Non-Redundant Activities of Interferon-Inducible CXC Chemokine Receptor 3 Ligands

(2018) Mieke Metzemaekers et al.   Frontiers in Immunology

Past, Present, and Future of Rituximab—The World’s First Oncology Monoclonal Antibody Therapy

(2018) Timothy M. Pierpont et al.   Frontiers in Oncology

Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice

(2018) Grégory Ehx et al.   Frontiers in Immunology

Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma

(2018) Jun Zhang et al.   Frontiers in Oncology

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

In Vivo Imaging Sheds Light on Immune Cell Migration and Function in Cancer

(2017) Tommaso Torcellan et al.   Frontiers in Immunology

Diffuse Large B-Cell Lymphoma: Current Strategies and Future Directions

(2017) Jennifer L. Cultrera et al.   Cancer Control

Clinical approach to diffuse large B cell lymphoma

(2016) Paolo F. Caimi et al.   BLOOD REVIEWS

CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer

(2016) Holger Bronger et al.   BRITISH JOURNAL OF CANCER

2016 US lymphoid malignancy statistics by World Health Organization subtypes

(2016) Lauren R. Teras et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

(2016) M. Bacac et al.   CLINICAL CANCER RESEARCH

In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing

(2016) S. Lehmann et al.   CLINICAL CANCER RESEARCH

The cytotoxic T lymphocyte immune synapse at a glance

(2016) Nele M. G. Dieckmann et al.   JOURNAL OF CELL SCIENCE

CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors

(2016) Marina Bacac et al.   OncoImmunology

Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints

(2015) M. E. Mikucki et al.   Nature Communications

Bispecific T-cell engagers for cancer immunotherapy

(2014) Amelia M Huehls et al.   IMMUNOLOGY AND CELL BIOLOGY

The Immunological Synapse

(2014) M. L. Dustin   Cancer Immunology Research

Oncology Meets Immunology: The Cancer-Immunity Cycle

(2013) Daniel S. Chen et al.   IMMUNITY

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

The emerging role of CXCL10 in cancer (Review)

(2011) MINGLI LIU et al.   Oncology Letters

Sustained LFA-1 cluster formation in the immune synapse requires the combined activities of L-plastin and calmodulin

(2010) Guido H. Wabnitz et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies

(2009) Gudrun E. Koehl et al.   CLINICAL & EXPERIMENTAL METASTASIS

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110

(2009) Cornelia Haas et al.   IMMUNOBIOLOGY

Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice

(2008) Béatrice Breart et al.   JOURNAL OF CLINICAL INVESTIGATION

Regulatory T Cells: Mechanisms of Differentiation and Function

(2007) Steven Z. Josefowicz et al.   Annual Review of Immunology